Author:
Clerico Marinella,De Mercanti Stefania Federica,Signori Alessio,Iudicello Marco,Cordioli Cinzia,Signoriello Elisabetta,Lus Giacomo,Bonavita Simona,Lavorgna Luigi,Maniscalco Giorgia Teresa,Curti Erica,Lorefice Lorena,Cocco Eleonora,Nociti Viviana,Mirabella Massimiliano,Baroncini Damiano,Mataluni Giorgia,Landi Doriana,Petruzzo Martina,Lanzillo Roberta,Gandoglia Ilaria,Laroni Alice,Frangiamore Rita,Sartori Arianna,Cavalla Paola,Costantini Gianfranco,Sormani Maria Pia,Capra Ruggero
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Neurology (clinical),Pharmacology
Reference36 articles.
1. Stüve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri®) in inflammatory diseases. CNS Drug Rev. 2007 Spring;13(1):79–95.
2. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/16510744
. Accessed 27 May 2019
3. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue E-W, et al. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. N Engl J Med. 2006;354(9):911–23.
4. Sehr T, Proschmann U, Thomas K, Marggraf M, Straube E, Reichmann H, et al. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. J Neuroinflammation. 2016;13(1):164.
https://doi.org/10.1186/s12974-016-0635-2
5. Kleinschmidt-DeMasters BK, Tyler KL. Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis. N Engl J Med 2005;353(4):369–74.